Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057402 | 0.83 | KDM4E (0.52) | KDM4EALDH1A1TSHRHTTLMNA | |
| SCHEMBL21057411 | 0.83 | KDM4E (0.57) | KDM4EALDH1A1TSHRHTTLMNA | |
| SCHEMBL21057535 | 0.81 | L3MBTL1 (0.52) | KDM4ELMNAEGFRHPGDMAPT | |
| SCHEMBL21057399 | 0.78 | ADORA3 (0.52) | KDM4EALDH1A1TSHRHTTLMNA | |
| SCHEMBL9477531 | 0.77 | NPSR1 (0.53) | KDM4EALDH1A1TSHRHTTLMNA | |
| SCHEMBL21057303 | 0.76 | ALDH1A1 (0.51) | KDM4EALDH1A1TSHRHTTLMNA | |
| SCHEMBL9477005 | 0.74 | ALDH1A1 (0.54) | KDM4EALDH1A1TSHRHTTLMNA | |
| SCHEMBL4928309 | 0.72 | ALDH1A1 (0.52) | KDM4EALDH1A1TSHRHTTLMNA | |
| SCHEMBL9477387 | 0.71 | HTT (0.51) | KDM4EALDH1A1TSHRHTTLMNA | |
| SCHEMBL21159608 | 0.71 | KDR (0.51) | KDRKDM4ETSHRHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | AKR1C3 1754/4885AKR1C2 1695/4885KDR 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.